Stuart Cobb Biography and Net Worth

Chief Scientific Officer of Neurogene

Stuart Cobb, Ph.D., is Chief Scientific Officer at Neurogene. Dr. Cobb, who joined Neurogene in 2019, brings to the team more than 20 years of experience in translational neuroscience. He leads Neurogene’s scientific research, the development of scientific strategy to support the company’s existing and growing gene therapy portfolio, and efforts to identify novel technologies that complement Neurogene’s pipeline. In addition to his role at Neurogene, Dr. Cobb also leads a research team at the University of Edinburgh, where he is Professor of Translational Neuroscience at Simons Initiative in the Developing Brain and Centre for Discovery Brain Sciences. Prior to his work at Neurogene, Dr. Cobb was a Caledonian Research Fellow and led an academic research laboratory at the University of Glasgow. His research has focused on developing novel genetic treatments for brain disorders based on a deep understanding of the molecular and cellular pathology. Dr. Cobb’s work has been published in leading journals and includes seminal work on the inherent reversibility of neurological features in neurodevelopmental disease. Dr. Cobb has a B.Sc. from the University of Glasgow and a Ph.D. in Neuroscience from the University of Oxford.

What is Stuart Cobb's net worth?: The estimated net worth of Stuart Cobb is at least $440.00 thousand as of May 14th, 2025. Dr. Cobb owns 20,794 shares of Neurogene stock worth more than $440,001 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Cobb may own. Additionally, Dr. Cobb receives a salary of $478,810.00 as Chief Scientific Officer at Neurogene. Learn More about Stuart Cobb's net worth.
How old is Stuart Cobb?: Dr. Cobb is currently 54 years old. There are 4 older executives and no younger executives at Neurogene. Learn More on Stuart Cobb's age.
What is Stuart Cobb's salary?: As the Chief Scientific Officer of Neurogene Inc., Dr. Cobb earns $478,810.00 per year. There are 2 executives that earn more than Dr. Cobb. The highest earning executive at Neurogene is Dr. Rachel L. McMinn Ph.D., Founder, Executive Chair & CEO, who commands a salary of $676,540.00 per year. Learn More on Stuart Cobb's salary.
How do I contact Stuart Cobb?: The corporate mailing address for Dr. Cobb and other Neurogene executives is 535 W 24th Street, 5th Floor, New York, NY 10011, United States. Neurogene can also be reached via phone at (877) 237-5020 and via email at [email protected]. Learn More on Stuart Cobb's contact information.
Has Stuart Cobb been buying or selling shares of Neurogene?: Stuart Cobb has not been actively trading shares of Neurogene during the last quarter. Most recently, Stuart Cobb sold 6,797 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $15.15, for a transaction totalling $102,974.55. Following the completion of the sale, the insider now directly owns 20,794 shares of the company's stock, valued at $315,029.10. Learn More on Stuart Cobb's trading history.
Who are Neurogene's active insiders?: Neurogene's insider roster includes Stuart Cobb (Chief Scientific Officer), and Rachel McMinn (CEO). Learn More on Neurogene's active insiders.
Are insiders buying or selling shares of Neurogene?: In the last year, insiders at the sold shares 2 times. They sold a total of 11,298 shares worth more than $179,221.49. The most recent insider tranaction occured on May, 14th when insider Stuart Cobb sold 6,797 shares worth more than $102,974.55. Insiders at Neurogene own 11.6% of the company. Learn More about insider trades at Neurogene.
Information on this page was last updated on 5/14/2025.

Stuart Cobb Insider Trading History at Neurogene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/14/2025	Sell	6,797	$15.15	$102,974.55	20,794

Stuart Cobb Buying and Selling Activity at Neurogene

Neurogene Company Overview

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Today's Range

Now: $21.16

$19.88

$23.00

50 Day Range

MA: $26.02

$17.33

$34.37

2 Week Range

Now: $21.16

$6.88

$37.27

Volume

450,545 shs

Average Volume

219,681 shs

Market Capitalization

$327.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Stuart Cobb Biography and Net Worth

What is Stuart Cobb's net worth?

How old is Stuart Cobb?

What is Stuart Cobb's salary?

How do I contact Stuart Cobb?

Has Stuart Cobb been buying or selling shares of Neurogene?

Who are Neurogene's active insiders?

Are insiders buying or selling shares of Neurogene?